Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLN | Q9BYT8 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30401731 | 0.99 | NLN (0.36) | NLNMEN1USP2ALDH1A1MAPT | |
| SCHEMBL14151247 | 0.93 | NLN (0.39) | NLN | |
| SCHEMBL7624042 | 0.89 | NLN (0.42) | NLN | |
| SCHEMBL3000079 | 0.89 | NLN (0.37) | NLN | |
| SCHEMBL7624049 | 0.89 | NLN (0.42) | NLN | |
| SCHEMBL13080959 | 0.87 | DPP7 (0.38) | NLN | |
| SCHEMBL9847297 | 0.86 | MME (0.37) | NLN | |
| Hydrochloric Acid SCHEMBL5263726 | 0.86 | NLN (0.38) | NLN | |
| SCHEMBL8388715 | 0.86 | GNAI3 (0.39) | NLN | |
| SCHEMBL18381248 | 0.86 | MME (0.37) | NLN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409517-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-12-12 | — | — | US | claimed |
| EP-4415561-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2024-08-21 | — | — | EP | claimed |
| WO-2023062110-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2023-04-20 | — | — | WO | claimed |
| US-20240409517-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-12-12 | — | — | US | disclosed |
| EP-4415561-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023062110-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2023-04-20 | — | — | WO | disclosed |
| US-20140155419-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-5519006-A | Phosphonated arylethanolamine compounds with anti-hyperglycemic and/or anti-obesity activity | SMITHKLINE BEECHAM PLC (GB) | 1996-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409517-A1 | ORGANIC COMPOUNDS | HTR3C, HTR3A, H1-0 | NLN 2675/4885MEN1 1452/4885USP2 4240/4885 |
| US-20140155419-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | NLN 2757/4885MEN1 4672/4885USP2 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.